These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 2436199)

  • 1. Immunohistochemical demonstration of cytokeratins in the human prostate.
    Wernert N; Seitz G; Goebbels R; Dhom G
    Pathol Res Pract; 1986 Dec; 181(6):668-74. PubMed ID: 2436199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Immunohistochemistry of the prostate and prostate carcinomas].
    Wernert N
    Veroff Pathol; 1991; 135():1-163. PubMed ID: 2038892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical investigation of different cytokeratins and vimentin in the prostate from the fetal period up to adulthood and in prostate carcinoma.
    Wernert N; Seitz G; Achtstätter T
    Pathol Res Pract; 1987 Oct; 182(5):617-26. PubMed ID: 2446293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Keratin immunoreactivity in the benign and neoplastic human prostate.
    Brawer MK; Peehl DM; Stamey TA; Bostwick DG
    Cancer Res; 1985 Aug; 45(8):3663-7. PubMed ID: 2410099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical expression of prostate specific antigen (PSA) in benign and malignant tumors of the prostate.
    Dema A; Tudose N
    Rom J Morphol Embryol; 1998; 44(1-4):93-100. PubMed ID: 15678849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostatic neuroendocrine cells have a unique keratin expression pattern and do not express Bcl-2: cell kinetic features of neuroendocrine cells in the human prostate.
    Xue Y; Verhofstad A; Lange W; Smedts F; Debruyne F; de la Rosette J; Schalken J
    Am J Pathol; 1997 Dec; 151(6):1759-65. PubMed ID: 9403726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intermediate cells in human prostate epithelium are enriched in proliferative inflammatory atrophy.
    van Leenders GJ; Gage WR; Hicks JL; van Balken B; Aalders TW; Schalken JA; De Marzo AM
    Am J Pathol; 2003 May; 162(5):1529-37. PubMed ID: 12707036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical distribution of the three predominant secretory proteins in the parenchyma of hyperplastic and neoplastic prostate glands.
    Abrahamsson PA; Lilja H; Falkmer S; Wadström LB
    Prostate; 1988; 12(1):39-46. PubMed ID: 2450341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Human prostatic tissue specific antigens: a model for the research of monoclonal antibodies against unknown antigens].
    Yoshiki T; Okada Y; Tomoyoshi T; Ueda M; Ogawa O; Yoshida O
    Hinyokika Kiyo; 1993 Mar; 39(3):213-9. PubMed ID: 7685139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.
    Stamey TA; Yang N; Hay AR; McNeal JE; Freiha FS; Redwine E
    N Engl J Med; 1987 Oct; 317(15):909-16. PubMed ID: 2442609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A theoretical rationale on the histogenesis of premalignant lesions and early carcinoma of the prostate.
    Botticelli AR
    Pathologica; 1994 Apr; 86(2):128-41. PubMed ID: 7524011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in keratin expression during the development of benign prostatic hyperplasia.
    Xue Y; Smedts F; Umbas R; Aalders TW; Debruyne FM; de la Rosette JJ; Schalken JA
    Eur Urol; 1997; 32(3):332-8. PubMed ID: 9358223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Keratin patterns in prostatic hyperplasia and adenocarcinoma.
    Svanholm H; Nielsen B; Starklint H
    APMIS Suppl; 1988; 4():100-8. PubMed ID: 2465010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of prostate-specific antigen and prostatic acid phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia.
    Bogdanowicz JF; Bentvelsen FM; Oosterom R; Schroeder FH
    Scand J Urol Nephrol Suppl; 1991; 138():97-103. PubMed ID: 1723815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in immunohistochemical staining in prostatic adenocarcinoma following diethylstilbestrol therapy.
    Grignon D; Troster M
    Prostate; 1985; 7(2):195-202. PubMed ID: 2413432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prostate-specific antigen. A new biological serum marker for prostatic adenocarcinoma].
    Haukaas S; Skaarland E; Halvorsen OJ; Stensland E; Farstad M
    Tidsskr Nor Laegeforen; 1990 Sep; 110(23):2990-3. PubMed ID: 1700496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunocytochemical evaluation of human prostatic carcinomas for carcinoembryonic antigen, nonspecific cross-reacting antigen, beta-chorionic gonadotrophin, and prostate-specific antigen.
    Purnell DM; Heatfield BM; Trump BF
    Cancer Res; 1984 Jan; 44(1):285-92. PubMed ID: 6197163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coordinate expression of cytokeratins 7 and 20 in prostate adenocarcinoma and bladder urothelial carcinoma.
    Bassily NH; Vallorosi CJ; Akdas G; Montie JE; Rubin MA
    Am J Clin Pathol; 2000 Mar; 113(3):383-8. PubMed ID: 10705819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of PAP and PSA gene expression in prostatic hyperplasia and prostatic carcinoma using northern-blot analyses, in situ hybridization and immunohistochemical stainings with monoclonal and bispecific antibodies.
    Hakalahti L; Vihko P; Henttu P; Autio-Harmainen H; Soini Y; Vihko R
    Int J Cancer; 1993 Oct; 55(4):590-7. PubMed ID: 7691762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical demonstration of tumor-associated antigens in prostatic carcinomas of various histological differentiations.
    Friedmann W; Steffens J; Lobeck H; Blümcke S; Nagel R
    Eur Urol; 1985; 11(1):52-6. PubMed ID: 2580711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.